These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 26856949

  • 1. Reducing clinical trial risk in multiple sclerosis.
    De Gasperis-Brigante CD, Parker JL, O'Connor PW, Bruno TR.
    Mult Scler Relat Disord; 2016 Jan; 5():81-8. PubMed ID: 26856949
    [Abstract] [Full Text] [Related]

  • 2. Risk of failure of a clinical drug trial in patients with moderate to severe rheumatoid arthritis.
    Jayasundara KS, Keystone EC, Parker JL.
    J Rheumatol; 2012 Nov; 39(11):2066-70. PubMed ID: 22942261
    [Abstract] [Full Text] [Related]

  • 3. Clinical trial success rates of anti-obesity agents: the importance of combination therapies.
    Hussain HT, Parker JL, Sharma AM.
    Obes Rev; 2015 Sep; 16(9):707-14. PubMed ID: 26222385
    [Abstract] [Full Text] [Related]

  • 4. Clinical trial risk in type-2 diabetes: importance of patient history.
    Aiyere EO, Silverberg J, Ali S, Parker JL.
    J Pharm Pharm Sci; 2014 Sep; 17(3):393-400. PubMed ID: 25224350
    [Abstract] [Full Text] [Related]

  • 5. Effect of applying inclusion and exclusion criteria of phase III clinical trials to multiple sclerosis patients in routine clinical care.
    Jalusic KO, Ellenberger D, Rommer P, Stahmann A, Zettl U, Berger K.
    Mult Scler; 2021 Oct; 27(12):1852-1863. PubMed ID: 33467978
    [Abstract] [Full Text] [Related]

  • 6. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 7. The success rate of new drug development in clinical trials: Crohn's disease.
    Parker JL, Clare Kohler J.
    J Pharm Pharm Sci; 2010 Apr; 13(2):191-7. PubMed ID: 20816005
    [Abstract] [Full Text] [Related]

  • 8. Lessons learned from independent central review.
    Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J.
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [Abstract] [Full Text] [Related]

  • 9. Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancer.
    Falconi A, Lopes G, Parker JL.
    J Thorac Oncol; 2014 Feb; 9(2):163-9. PubMed ID: 24419412
    [Abstract] [Full Text] [Related]

  • 10. Nocebo effects in multiple sclerosis trials: a meta-analysis.
    Papadopoulos D, Mitsikostas DD.
    Mult Scler; 2010 Jul; 16(7):816-28. PubMed ID: 20538704
    [Abstract] [Full Text] [Related]

  • 11. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M, Kondo T, Tanaka M.
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [Abstract] [Full Text] [Related]

  • 12. Novel therapeutic options for multiple sclerosis.
    Curtin F, Hartung HP.
    Expert Rev Clin Pharmacol; 2014 Jan; 7(1):91-104. PubMed ID: 24325127
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
    Wiese MD, Rowland A, Polasek TM, Sorich MJ, O'Doherty C.
    Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1025-35. PubMed ID: 23682862
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Effect of Biomarkers on Clinical Trial Risk in Gastric Cancer.
    Dhillon S, Lopes G, Parker JL.
    Am J Clin Oncol; 2023 Feb 01; 46(2):58-65. PubMed ID: 36662871
    [Abstract] [Full Text] [Related]

  • 17. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH, Eisenhauer EA.
    J Clin Oncol; 2008 Mar 10; 26(8):1346-54. PubMed ID: 18285606
    [Abstract] [Full Text] [Related]

  • 18. Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs.
    Bugano DDG, Hess K, Jardim DLF, Zer A, Meric-Bernstam F, Siu LL, Razak ARA, Hong DS.
    Clin Cancer Res; 2017 Aug 01; 23(15):4020-4026. PubMed ID: 28377482
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Current and future disease-modifying therapies in multiple sclerosis.
    Lim SY, Constantinescu CS.
    Int J Clin Pract; 2010 Apr 01; 64(5):637-50. PubMed ID: 20456216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.